Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05584189 · ClinicalTrials.gov registry record · NA
COVID-19 MP Biomedicals Rapid SARS-CoV-2 Antigen Test Usability
A NA study, sponsored by MP Biomedicals.
- Completed
- Registry status
- NA
- Development phase
- 99
- Enrollment target
NCT05584189: Completed NA study, sponsored by MP Biomedicals.
NCT05584189 is a NA study that has completed, run by MP Biomedicals. The registered enrollment target is 99 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05584189, a NA study, has completed, sponsored by MP Biomedicals.
- COMPLETED
- Registry status
- NA
- Development phase
- 99 participants
- Enrollment target
Study Summary
SARS-CoV-2 rapid antigen over the counter usability study.
Primary Outcome
Lay subjects aged 14-65+ who will perform collection of the candidate Ag self-test kit on themselves under the supervision of qualified site personnel in person.
Interventions
- DEVICE Rapid SARS-CoV-2 Antigen Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2021-10-07 |
| Est. Completion | 2021-10-27 |
| Phase | NA |
What the finished NCT05584189 record still lists
NCT05584189 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which Rapid SARS-CoV-2 Antigen Test is the first listed.
NCT05584189 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05584189 about?
NCT05584189 is a clinical study titled "COVID-19 MP Biomedicals Rapid SARS-CoV-2 Antigen Test Usability". SARS-CoV-2 rapid antigen over the counter usability study.
What is the current status of trial NCT05584189?
This trial is currently completed. It is a NA study. The enrollment target is 99 participants. The study started on 2021-10-07. Estimated completion is 2021-10-27.
What interventions are being tested in trial NCT05584189?
The interventions under investigation include: Rapid SARS-CoV-2 Antigen Test (DEVICE).
Who is sponsoring clinical trial NCT05584189?
This trial is sponsored by MP Biomedicals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05584189's enrollment target sits among peer trials
99 920th of 2000 higher than 1,079 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI